AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor pediatric tablets
Description: A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor pediatric tablets suspended in water
Description: A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor pediatric tablets suspended in water
Description: A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor immediate release (IR) tablets (Commercial tablet)
Description: A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
Study NCT03126695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor immediate release (IR) tablets (Commercial tablet)
Description: A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
Study NCT02171611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate pellets
Study NCT02171611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate powder
Study NCT02171611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate capsule
Study NCT02340338 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rTSST-1 Variant Candidate Vaccine
Description: In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of \< 20 to > 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized.
Study NCT02340338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTSST-1 Variant Candidate Vaccine
Description: In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of \< 20 to > 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized.
Study NCT02124278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Study NCT02124278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PUL-042 Inhalation Solution
Study NCT03350295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
Study NCT04143009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Friendship Bench
Description: EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
Study NCT04143009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard Care (Control)
Description: Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
Study NCT04143009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Friendship Bench
Description: Adapted Friendship Bench (AFB): AFB will include the following: integrating problem solving therapy- based and antiretroviral therapy (ART) adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
Study NCT03704142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound World Solutions CS50+
Description: Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
Study NCT03704142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tweak Focus
Description: Participants will be tested using the Tweak Focus hearing devices.
Study NCT03704142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQ Earbuds
Description: Participants will be tested using the IQ Earbuds hearing devices.
Study NCT03704142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bose Hearphones
Description: Participants will be tested using the Bose Hearphones hearing devices.
Study NCT03268928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Story Starters Intervention
Description: Shared reading intervention
Study NCT03268928 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list Control
Description: Wait-list control
Study NCT04979689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Description: Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
Study NCT04979689 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non intensive physical therapy
Description: Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
Study NCT01853995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Lingual Mandibular Growth Modificator (FLMGM)
Description: New Class II Corrector
Study NCT01157754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel and ethynilestradiol
Study NCT01157754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel and ethynilestradiol
Study NCT02986503 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin+cisplatin+ifosfamide
Description: Chemotherapy for Good responder high grade osteosarcoma
Study NCT02986503 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin+cisplatin+ifosfamide+methotrexate
Description: Chemotherapy for Poor responder high grade osteosarcoma
Study NCT04247958 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal resection
Description: Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
Study NCT03497585 — intervention group
Intervention type: BEHAVIORAL
Intervention: Activity pacing framework
Description: The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
Study NCT01771055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Galactose dripped into the abdomen after surgery
Study NCT01771055 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard surgical methods
Study NCT00548015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: state-of-the art strategy and extented strategy
Description: state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
Study NCT00548015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: state-of-the art strategy and extented strategy
Description: state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
Study NCT02908256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geloplasma (PVI)
Description: In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
Study NCT02908256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Geloplasma (delta PP)
Description: In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
Study NCT01718561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SARI
Description: The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
Study NCT04309942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Clinical Pharmacy Consultation
Description: These patients will have the benefit of a Guided Clinical Pharmacy Consultation
Study NCT01159028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001
Description: Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
Study NCT01159028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 in combination with LDAC
Description: Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
Study NCT03028870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V120083
Description: Capsules
Study NCT03028870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Capsules
Study NCT03028870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules to match V120083 and/or naproxen
Study NCT03028870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match V120083 and/or naproxen
Study NCT03028870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules to match V120083 and/or naproxen
Study NCT02075099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tensing exercises
Description: Donors will do tensing exercises during blood donation
Study NCT02075099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tensing exercises
Description: Donors will do tensing exercises during blood donation
Study NCT02075099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No tensing exercises
Description: Donors will not do tensing exercises during blood donation - control arm
Study NCT02075099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No tensing exercises
Description: Donors will not do tensing exercises during blood donation - control arm
Study NCT01673711 — intervention group
Intervention type: DRUG
Intervention: deuterated phenanthrene tetraol
Description: Given PO
Study NCT01673711 — intervention group
Intervention type: DRUG
Intervention: pharmacological study
Description: Correlative studies
Study NCT01673711 — intervention group
Intervention type: DRUG
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05193253 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment
Study NCT05193253 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment
Study NCT05193253 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
Study NCT02411162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy GSK2894512 Cream A + GSK2894512 Cream B
Description: GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.
Study NCT02411162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy Vehicle Cream A + Vehicle Cream B
Description: Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
Study NCT04355741 — intervention group
Intervention type: OTHER
Intervention: Exposure
Description: Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
Study NCT03955302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
Study NCT02572674 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental follow up
Description: Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
Study NCT02572674 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic sample
Description: Blood samples
Study NCT00708123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride toothpaste
Description: Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
Study NCT00708123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste
Description: Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
Study NCT00708123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: Fluoride free toothpaste (0 ppm F)
Study NCT02676089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 200/6/12.5 µg
Study NCT02676089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 200/6 µg
Study NCT02676089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Study NCT03235830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Standard of Care (ESoC) + Text
Description: See above in arm/group description
Study NCT03235830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care (ESoC)
Description: See above in arm/group description
Study NCT01231594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Study Drug
Study NCT01231594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Study Drug
Study NCT01231594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other approved anti-cancer agent
Description: Study Drug
Study NCT04041986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
Study NCT04041986 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
Study NCT04041986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
Study NCT03115736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
Study NCT02354066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hallux valgus Shoe
Description: Brake response measurement after surgery with this foot orthosis
Study NCT02354066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forefoot relief shoe
Description: Brake response measurement after surgery with this foot orthosis
Study NCT02354066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retail Shoe
Description: Brake response time measurement before surgery (control run)
Study NCT02374099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
Study NCT02374099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
Study NCT03763071 — intervention group
Intervention type: OTHER
Intervention: Patient-reported scales to measure sleep disorders
Description: Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters
Study NCT03022695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound